Compare Palo Alto Networks Inc (PANW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Palo Alto Networks IncTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Palo Alto Networks Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Palo Alto Networks Inc trades at $335.97 (market cap $273.11B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Palo Alto Networks Inc nearer its low. Which is the better fit depends on your goals.

	PANW	XBI
Market Cap	$273.11B	—
Sector	Technology	Broad Market / Factor
52-Week High	$396.00	$169.55
52-Week Low	$141.67	$93.43
Enterprise Value	$272.07B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $336.98, up 1.12% with a bearish technical signal but strong fundamentals. Revenue grew to $9.22B in 2025, with EPS beats in recent quarters. The stock faces high valuation multiples (P/E 293.03) and mixed sentiment amid AI-driven growth and recent price volatility.

Outlook: Growth is supported by AI security demand and platformization strategy, but risks include premium valuation and competitive pressures. Analyst consensus is bullish with a $410.48 price target, though technical indicators suggest near-term caution.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

PANW

Palo Alto Networks to present at Goldman Sachs Communacopia + Tech Conference on Sept 10PRNewsWire · 2 days agoNeutral S&P 100 ETF swaps Nike and Colgate for 4 AI tech stocks, signaling a shift to tech-heavy portfolios.24/7 Wall Street · 3 days agoNeutral Investors withdrew $700M from software ETF IGV before Snowflake's strong earnings report boosted the sector.24/7 Wall Street · 3 days agoNeutral View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.